文献速递心力衰竭与心肌病

克隆性造血与心力衰竭发病风险

Clonal Hematopoiesis and Incident Heart Failure.
PubMed 文献 · JAMA Cardiol · 2026-01-01

CAD、房颤、2型糖尿病和慢性肾病仅介导了非DNMT3A CHIP与心衰关联的28.2%,提示CHIP可能是心衰的独立风险因素和潜在治疗靶点。

要点

  • CHIP与心衰风险升高相关(aHR 1.27),非DNMT3A亚型关联更强(aHR 1.52)。
  • CAD、房颤、2型糖尿病和慢性肾病仅解释非DNMT3A CHIP与心衰关联的28.2%。

核心结论

  • CHIP尤其是非DNMT3A CHIP与心衰发病风险升高相关,且该关联仅少部分由CHIP相关共病介导,提示CHIP是心衰的独立风险因素和潜在治疗靶点。

主要发现

  • 中位随访11.1年期间,7183名(1.7%)发生 incident 心衰。

临床怎么用

  • 对于携带CHIP尤其非DNMT3A亚型的个体,应关注心衰风险,即使无传统心血管共病。
  • CHIP相关共病仅解释部分心衰风险,提示需探索CHIP本身的致病机制作为干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clonal hematopoiesis of indeterminate potential (CHIP), the age-related clonal expansion of hematopoietic cells with acquired preleukemic variants, has been associated with cardiometabolic diseases, including heart failure (HF). However, prior studies have lacked power to examine less common CHIP driver variants and have not investigated potential mediators of the CHIP-HF association. OBJECTIVE: To test whether specific CHIP subtypes are associated with incident HF and determine the extent to which CHIP-associated comorbidities mediate this association. DESIGN, SETTING, AND PARTICIPANTS: This was a UK Biobank prospective population-based cohort study of community-dwelling adults in the UK, with enrollment from 2006 to 2010 and follow-up through 2020. Included were participants with whole-exome sequencing (WES) and without prevalent HF, hematologic malignancy, or other CHIP-associated comorbidities (coronary artery disease [CAD], atrial fibrillation [AF], type 2 diabetes [T2D], or chronic kidney disease [CKD]) at baseline. Study data were analyzed from April through October 2025. EXPOSURES: Presence of CHIP and gene-specific CHIP subtypes (DNMT3A, non-DNMT3A, TET2, ASXL1, JAK2, DNA damage repair genes, and spliceosome genes). Mediation analyses examined CHIP-associated comorbidities (CAD, AF, T2D, and CKD). MAIN OUTCOMES AND MEASURES: The primary outcome was incident HF. Cox regression tested associations of CHIP and CHIP subtypes with incident HF, adjusted for age, sex, race, and cardiovascular risk factors. RESULTS: Among 417 616 participants (mean [SD] age, 56.1 [8.1] years; 234 868 female [56.2%]), 7183 (1.7%) developed incident HF over a median (IQR) of 11.1 (10.4-11.8) years of follow-up. CHIP was associated with HF risk (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.15-1.40; P < .001), driven by non-DNMT3A subtypes (aHR, 1.52; 95% CI, 1.33-1.75; P < .001), including associations with TET2, ASXL1, JAK2, and spliceosome CHIP. DNMT3A CHIP was more modestly associated with HF (aHR, 1.15; 95% CI, 1.00-1.31; P = .04). In mediation analyses, development of CAD, AF, T2D, and/or CKD collectively accounted for 28.2% of the association (95% CI, 11.6%-45.4%; P = .001) between non-DNMT3A CHIP and HF. CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that CHIP, especially non-DNMT3A CHIP, was associated with incident HF. Other CHIP-associated comorbidities explained only a minority of the association between non-DNMT3A CHIP and HF. These findings suggest that CHIP is an HF risk factor and potential therapeutic target.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Flynn, Schuermans, Uddin, et al. Clonal Hematopoiesis and Incident Heart Failure. JAMA Cardiol. 2026. PMID: 41206888. doi:10.1001/jamacardio.2025.4603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。